GABA transaminase deficiency. Case report and literature review

Amira Oshi1, Abdullah Alfaifi1, Mohammed Z Seidahmed1

  • 1Department of Pediatrics Security Forces Hospital Riyadh Saudi Arabia.

Clinical Case Reports
|March 26, 2021
PubMed

Insights

GABA transaminase deficiency, a rare neurometabolic disorder, can cause early-onset epileptic encephalopathies. Early diagnosis is crucial for families, enabling genetic counseling and reproductive options like pre-implantation genetic diagnosis.

Area of Science:

  • Neurology
  • Metabolic Disorders
  • Genetics

Background:

  • Early-onset epileptic encephalopathies represent a diagnostic challenge.
  • Neurometabolic disorders are often rare and difficult to identify.
  • GABA transaminase deficiency is a specific, treatable cause of these conditions.

Observation:

  • A case study highlighted the post-mortem diagnosis of GABA transaminase deficiency in an infant.
  • The diagnosis occurred within a family with a history of unexplained infant neurological issues.
  • This rare neurometabolic disorder presented as severe epilepsy.

Findings:

  • GABA transaminase deficiency was confirmed as the cause of the infant's neurological condition.
  • The diagnosis was established through post-mortem examination.
  • Genetic analysis confirmed the specific deficiency.

Implications:

  • Increased vigilance for GABA transaminase deficiency can lead to earlier diagnoses in affected infants.
  • Genetic counseling is vital for families with rare neurometabolic disorders.
  • Reproductive options, such as pre-implantation genetic diagnosis, can be offered to at-risk families.

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
907
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
499
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.6K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
413